P4, N=124, Active, not recruiting, Beth Israel Deaconess Medical Center | Enrolling by invitation --> Active, not recruiting | Trial completion date: Dec 2026 --> Sep 2026 | Trial primary completion date: Dec 2026 --> Sep 2026

P3, N=180, Active, not recruiting, University of Chicago | Trial completion date: Nov 2026 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027

Combination therapy of nipocalimab with certolizumab showed a similar outcome in the primary endpoint and secondary endpoints compared with certolizumab monotherapy in participants with active RA.

Herein, we report the synthesis of lenalidomide (63% overall yield) and pomalidomide (62% overall yield) using an integrated continuous flow platform with residence times of 42 minutes and 52 minutes, respectively. The products are obtained without the need for column chromatography, and both immunomodulatory imide drugs (IMiDs) can be accessed from a common intermediate through our developed route. Furthermore, we explore the synthesis of CRBN ligand-linkers under continuous flow, affording a series of derivatives with diverse properties in yields exceeding 90%.

P2, N=30, Recruiting, Tom Appleton | Trial completion date: Nov 2025 --> Dec 2028 | Trial primary completion date: Nov 2025 --> Dec 2027

Potential therapeutic agents (e.g. capivasertib, lenalidomide) were predicted, and lenalidomide may represent a feasible initial treatment option for PTCL, with an objective response rate (ORR) of 40.0% and a maximum survival duration exceeding 50 months. NET-RGs play crucial roles in diagnosis, prognosis, and TME regulation, and lenalidomide, a putative TNF-targeting agent, may represent a feasible initial treatment option in PTCL.

P2, N=20, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Apr 2025 --> Jun 2026

CSF-1R blockade depleted these immunosuppressive macrophages, which correlated with decreased expression of inhibitory receptors and enhanced expression of activation markers in Tphex. Given the FDA approval of axatilimab for chronic GVHD, combining CSF-1R blockade with lenalidomide maintenance represents a readily testable strategy to improve progression-free survival after ASCT.

Among patients receiving bortezomib, lenalidomide, and dexamethasone (VRd) induction therapy, those with cytogenetic abnormalities showed significantly lower deep response rates (complete response + very good partial response). Furthermore, RB1 deletion or D13S319 deletion combined with other high-risk indicators further shortened PFS. These findings indicate that integrating expanded cytogenetic markers optimises MM risk stratification and provides a basis for individualised treatment strategies.

P1/2, N=120, Not yet recruiting, City of Hope Medical Center | Initiation date: Dec 2025 --> Mar 2026

The FCGR3A rs396991 CC genotype is significantly associated with improved infliximab pharmacokinetics and reduced immunogenicity in UC patients. These findings highlight the potential of FCGR3A genotyping to guide personalized therapeutic strategies and optimize clinical outcomes in UC.

P2, N=15, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Jan 2026 --> Jan 2027